Merck

ONTRUZANT

View Prices
  1. Home
    2.  / 
  2. Q Code
    3.  / ONTRUZANT – Q5112

Manufacturer:

Merck

Name:

ONTRUZANT

HCPCS Code Descriptor:

Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg

Category:

Q Code

HCPCS:

Q5112

NDC(s):

78206-0148-01, 78206-0147-01, 00006-5033-02

Primary Type:

Oncology Biosimilar

Generic Status:

Multi-Source

Route of Administration:

Intravenous

About:

ONTRUZANT is an Oncology Biosimilar drug manufactured by Merck and administered via the Intravenous route of administration. The Q Code: Q5112 is aligned to the drug ONTRUZANT.

Ontruzant (trastuzumab) is a cancer drug that targets the HER2 protein in cancer cells. This medication can be used to treat specific types of breast and stomach cancers. Ontruzant can be used in combination with other cancer medications. This drug is manufactured by Merck Sharp & Dohme and Organon and is biosimilar to the medication Herceptin (J9356). Ontruzant has one HCPCS code Q5112, which has been aligned to the medication since July 2019. Patient assistance programs for this medication can be found through the Organon Access Program.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

7/1/19

HCPCS Effective Date:

7/1/19

HCPCS Short Description:

Inj ontruzant 10 mg

Billing and Coding Guide:

Not Found

Patient Assistance:

https://www.organonaccessprogram-ontruzant.com/hcc/

ONTRUZANT - Q5112